Monday, September 8, 2025

Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm

Related stories

Cerence AI Brings Microsoft 365 Copilot to Cars for Work

Cerence, a global leader in conversational AI-powered user experiences,...

Smarsh Uses Salesforce Agentforce to Launch AI Support Agents

Smarsh, the global leader in communications data and intelligence,...

Redis to Acquire Decodable to Boost Real-Time Data Platform

Redis, the leading real-time data platform, announced its intention...

Ketryx Raises $39M Series B to Advance AI in Life Sciences

Ketryx, the AI-driven compliance platform that helps life sciences...

Snap Inc. Unveils Imagine Lens, Revolutionizing Creative Expression with AI

Snap Inc., the pioneer in camera technology and creative...
spot_imgspot_img

Cutting-edge tool analyzes data from cardiac remote monitoring devices to assess whether a patient is at high risk of experiencing worsening heart failure, enabling medical teams to intervene and avoid hospitalization.

Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new groundbreaking algorithm, SignalHF, used in its remote monitoring solution.

Implicity was the first private company authorized to access the Health Data Hub, one of the largest databases of patients with heart disease in the world. Based on the Health Data Hub complete medico-administrative database and comprehensive datasets from Implicity’s AI-based remote monitoring platform, the Implicity team trained and validated a machine learning algorithm that assesses the risk of future heart failure events, enabling physicians to intervene before a patient requires hospitalization.

“Heart failure remains a significant healthcare challenge, contributing to approximately one million hospitalizations each year. Preventing even a portion of these would be a game-changer in cardiac care,” said Dr. Arnaud Rosier, Implicity’s CEO and cardiologist.  “SignalHF is an innovative and effective tool that physicians can use to assess risk of hospitalization due to heart failure earlier, enabling interventions that can lead to better outcomes and reduce hospital admissions.”

Also Read: RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of Cardiac Implantable Electronic Devices (CIED), including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices (CRT-P, CRT-D) from Biotronik, Boston Scientific and Medtronic. SignalHF is the first pacemaker compatible heart failure algorithm on the market. The algorithm can accurately identify trends indicating whether a patient’s condition is worsening. Care teams receive an automatic alert when the patient’s risk score crosses an established threshold, indicating an individual is at high risk of experiencing heart failure and being hospitalized in the near future.

“Comprehensive heart failure management includes treatment, prevention, and personalization. Implicity’s solution is part of this approach. Our alerts are generated in context with a patient’s medical profile to help personalize care management plans. Furthermore, 75% of the alerts preceding a patient hospitalization are sent at least 14 days in advance  – offering a two-week window to adjust medications or take proactive measures,” said Issam Ibnouhsein, Head of Data at Implicity.

Source: PRNewsWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img